Susanne Beck

发表

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

J. Moreaux, D. Hose, H. Goldschmidt, 2019, Journal of Hematology & Oncology.

Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model

D. Hose, H. Goldschmidt, S. Ševčíková, 2020, British journal of haematology.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

D. Hose, A. Jauch, A. Ho, 2018, Front. Immunol..

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

S. Fröhling, D. Kazdal, J. Budczies, 2022, British Journal of Cancer.

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types

D. Kazdal, J. Budczies, T. Seufferlein, 2022, The journal of pathology. Clinical research.

Iron-Bound Lipocalin-2 Protects Renal Cell Carcinoma from Ferroptosis

B. Brüne, T. Schmid, A. Daiber, 2021, Metabolites.

Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma

G. Tabatabai, M. Tatagiba, C. Ries, 2021, Cancers.

Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer

W. Weichert, J. Budczies, B. Wollenberg, 2023, British Journal of Cancer.

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis

D. Kazdal, J. Budczies, T. Stiewe, 2023, Cell death discovery.

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)

S. Fröhling, D. Kazdal, J. Budczies, 2023, Translational oncology.

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

A. Jauch, A. Seckinger, U. Bertsch, 2024, JCO precision oncology.